231 related articles for article (PubMed ID: 32332210)
1. Breakthrough cancer pain in 2020.
Løhre ET; Thronæs M; Klepstad P
Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
7. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Husic S; Imamovic S; Matic S; Sukalo A
Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843
[TBL] [Abstract][Full Text] [Related]
9. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Überall MA
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
[TBL] [Abstract][Full Text] [Related]
10. Fentanyl for breakthrough cancer pain: where are we?
Meriggi F; Zaniboni A
Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Zucco F; Bonezzi C; Fornasari D
Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
[TBL] [Abstract][Full Text] [Related]
12. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
13. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
14. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Alberts DS; Smith CC; Parikh N; Rauck RL
Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
[TBL] [Abstract][Full Text] [Related]
15. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough cancer pain: review and calls to action to improve its management.
Camps Herrero C; Batista N; Díaz Fernández N; Escobar Álvarez Y; Gonzalo Gómez A; Isla Casado D; Salud A; Terrasa Pons J; Guillem Porta V
Clin Transl Oncol; 2020 Aug; 22(8):1216-1226. PubMed ID: 32002739
[TBL] [Abstract][Full Text] [Related]
18. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
19. Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study.
Alarcón MDL; Estévez FV; Cabezón-Gutiérrez L; Padrós MC; Martín-Arroyo JMT; Rebollo MA; Jiménez-López AJ; Sanz-Yagüe A
J Geriatr Oncol; 2019 Jul; 10(4):643-652. PubMed ID: 31036463
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.
Davies AN; Elsner F; Filbet MJ; Porta-Sales J; Ripamonti C; Santini D; Webber K
BMJ Support Palliat Care; 2018 Sep; 8(3):241-249. PubMed ID: 29875184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
